The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma

Digestive Diseases and Sciences

Volumn 56, Issue 8, 2011, Pages 2491-2496

  Singh, Sundeep ^a   Tang, Shou Jiang ^b   Sreenarasimhaiah, Jayaprakash ^c   Lara, Luis F ^d   Siddiqui, Ali ^e  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

CA19 9; Cholangiocarcinoma; Pancreatic cancer; Serum carbohydrate antigen

Indexed keywords

CA 19-9 ANTIGEN;

ABDOMINAL PAIN; ARTICLE; BILE DUCT CARCINOMA; BILE DUCT OBSTRUCTION; CANCER DIAGNOSIS; COMMON BILE DUCT STONE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DYSPNEA; EDEMA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; JAUNDICE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MUSCULOSKELETAL PAIN; PANCREAS CANCER; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; STOMACH DISTENSION; UNIVERSITY HOSPITAL; WEAKNESS;

ADENOMA; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CA-19-9 ANTIGEN; CHOLANGIOCARCINOMA; CHOLEDOCHOLITHIASIS; CHOLESTASIS; FEMALE; HUMANS; JAUNDICE; MALE; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 79960939958     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-011-1709-8     Document Type: Article

References (11)

1. Koprowski H, Steplewski Z, Mitchell K, et al. Colorectal carcinoma antigen detected by hybridoma antibodies. Somatic Cell Genet. 1979;5:957-972.
2. Itkowitz SH, Kim YS. New carbohydrate tumor markers. Gastroenterology. 1986;90:491-494. (Pubitemid 16136697)
3. Tempero MA, Uchida E, Takasaki H, et al. Relationship of carbohydrate antigen and Lewis antigens in pancreatic cancer. Cancer Res. 1987;47:5501-5503. (Pubitemid 17152971)
4. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33:266-270. (Pubitemid 46488663)
5. Steinberg W. The clinical utility of the CA19-9 tumor-associated antigen. Am J Gastroenterol. 1990;85:350-355. (Pubitemid 20140602)
6. Andriulli A, Gindro T, Plantino P, et al. Prospective evaluation of the diagnostic efficacy of CA19-9 assay as a marker for gastrointestinal cancers. Digestion. 1986;33:26-33. (Pubitemid 16222267)
7. Uygur-Bayramicli O, Dabak R, Orbay E, et al. Type 2 diabetes mellitus and CA19-9 levels. World J Gastroenterol. 2007;13:5537-5539.
8. Mertz HR, Sechopoulos P, Delbeke D, et al. EUS, PET, and CT scanning for evaluation of pancreatic adenocarcinoma. Gastrointest Endosc. 2000;52:367-371.
9. Sreenarasimhaiah J. Efficacy of endoscopic ultrasound in characterizing mass lesions in chronic pancreatitis. J Clin Gastroenterol. 2008;42:81-85.
10. Mishra G, Conway JD. Endoscopic ultrasound in the evaluation of radiologic abnormalities of the liver and biliary tree. Curr Gastroenterol Rep. 2009;11:150-154.
11. Mann DV, Edwards R, Ho S, et al. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol. 2000;26:474-479.